false2021-06-302021Q20001627281--12-31These costs correspond to the issuance costs related to the At-The-Market (“ATM”) financing program were recorded as a reduction of share premium, in anticipation of share issuances that occurred in April 2021 0001627281 2020-01-01 2020-06-30 0001627281 2021-01-01 2021-06-30 0001627281 2020-04-01 2020-06-30 0001627281 2021-04-01 2021-06-30 0001627281 2020-12-31 0001627281 2021-06-30 0001627281 2020-06-30 0001627281 2019-12-31 0001627281 country:FR 2021-06-30 0001627281 ifrs-full:PreviouslyStatedMember country:FR 2021-06-30 0001627281 ifrs-full:NotLaterThanOneYearMember 2021-06-30 0001627281 ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember 2021-06-30 0001627281 ifrs-full:LaterThanFiveYearsMember 2021-06-30 0001627281 clls:CalyxtMember 2021-06-30 0001627281 clls:AtmFinancingProgramMember 2021-06-30 0001627281 clls:LicenseAgreementsMember 2021-06-30 0001627281 clls:LicenseAgreementsMember ifrs-full:NotLaterThanOneYearMember 2021-06-30 0001627281 clls:LicenseAgreementsMember ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember 2021-06-30 0001627281 clls:LicenseAgreementsMember ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember 2021-06-30 0001627281 clls:LicenseAgreementsMember ifrs-full:LaterThanFiveYearsMember 2021-06-30 0001627281 clls:ManufacturingAgreementsMember 2021-06-30 0001627281 clls:ManufacturingAgreementsMember ifrs-full:NotLaterThanOneYearMember 2021-06-30 0001627281 clls:ClinicalAndRdAgreementsMember 2021-06-30 0001627281 clls:ClinicalAndRdAgreementsMember ifrs-full:NotLaterThanOneYearMember 2021-06-30 0001627281 clls:ClinicalAndRdAgreementsMember ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember 2021-06-30 0001627281 ifrs-full:ConstructionInProgressMember 2021-06-30 0001627281 ifrs-full:ConstructionInProgressMember ifrs-full:NotLaterThanOneYearMember 2021-06-30 0001627281 clls:OtherAgreementsMember 2021-06-30 0001627281 clls:OtherAgreementsMember ifrs-full:NotLaterThanOneYearMember 2021-06-30 0001627281 ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember 2021-06-30 0001627281 ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember 2021-06-30 0001627281 clls:ManufacturingAgreementsMember ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember 2021-06-30 0001627281 clls:ItLicensingAgreementsMember 2021-06-30 0001627281 clls:ItLicensingAgreementsMember ifrs-full:NotLaterThanOneYearMember 2021-06-30 0001627281 clls:ItLicensingAgreementsMember ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember 2021-06-30 0001627281 clls:ManufacturingFacilityMember 2021-06-30 0001627281 clls:CarryingAmountAndValueMember 2021-06-30 0001627281 clls:EstimatedFairValueMember 2021-06-30 0001627281 ifrs-full:TradingSecuritiesMember 2021-06-30 0001627281 ifrs-full:LandAndBuildingsMember 2021-06-30 0001627281 clls:TechnicalEquipmentMember 2021-06-30 0001627281 ifrs-full:FixturesAndFittingsMember 2021-06-30 0001627281 ifrs-full:BuildingsMember ifrs-full:RightofuseAssetsMember 2021-06-30 0001627281 ifrs-full:OfficeEquipmentMember ifrs-full:RightofuseAssetsMember 2021-06-30 0001627281 ifrs-full:RightofuseAssetsMember 2021-06-30 0001627281 stpr:NY 2021-06-30 0001627281 clls:StateGuaranteedLoanMember clls:MajorBorrowingTransactionsMember 2021-06-30 0001627281 clls:StateGuaranteedLoanMember clls:MajorBorrowingTransactionsMember ifrs-full:BottomOfRangeMember 2021-06-30 0001627281 clls:StateGuaranteedLoanMember clls:MajorBorrowingTransactionsMember ifrs-full:TopOfRangeMember 2021-06-30 0001627281 clls:RaleighAndParisMember clls:CellectisIncMember clls:AssetsPutInServiceMember 2021-06-30 0001627281 clls:RaleighsBuildingMember 2021-06-30 0001627281 clls:StonebriarsEquipmentMember 2021-06-30 0001627281 clls:CalyxtIncMember 2021-06-30 0001627281 ifrs-full:PlantsMember ifrs-full:OperatingSegmentsMember 2020-01-01 2020-06-30 0001627281 ifrs-full:OperatingSegmentsMember clls:TherapeuticsMember 2020-01-01 2020-06-30 0001627281 ifrs-full:OperatingSegmentsMember 2020-01-01 2020-06-30 0001627281 clls:EquityAwardsMember 2020-01-01 2020-06-30 0001627281 clls:CalyxtMember clls:StockOption1Member 2020-01-01 2020-06-30 0001627281 ifrs-full:LandAndBuildingsMember 2020-01-01 2020-06-30 0001627281 clls:TechnicalEquipmentMember 2020-01-01 2020-06-30 0001627281 ifrs-full:FixturesAndFittingsMember 2020-01-01 2020-06-30 0001627281 ifrs-full:ConstructionInProgressMember 2020-01-01 2020-06-30 0001627281 ifrs-full:EliminationOfIntersegmentAmountsMember clls:TherapeuticsMember 2020-01-01 2020-06-30 0001627281 ifrs-full:EliminationOfIntersegmentAmountsMember 2020-01-01 2020-06-30 0001627281 ifrs-full:EquityAttributableToOwnersOfParentMember 2020-01-01 2020-06-30 0001627281 ifrs-full:NoncontrollingInterestsMember 2020-01-01 2020-06-30 0001627281 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-06-30 0001627281 country:FR 2020-01-01 2020-06-30 0001627281 country:US 2020-01-01 2020-06-30 0001627281 ifrs-full:PlantsMember 2020-01-01 2020-06-30 0001627281 clls:TherapeuticsMember 2020-01-01 2020-06-30 0001627281 clls:EquityAwardsMember ifrs-full:BottomOfRangeMember 2020-01-01 2020-06-30 0001627281 clls:EquityAwardsMember ifrs-full:TopOfRangeMember 2020-01-01 2020-06-30 0001627281 clls:StockOption1Member 2020-01-01 2020-06-30 0001627281 clls:WarrantsMember 2020-01-01 2020-06-30 0001627281 clls:SAFreeSharesMember 2020-01-01 2020-06-30 0001627281 ifrs-full:RetainedEarningsMember 2020-01-01 2020-06-30 0001627281 clls:CurrencyTranslationAdjustmentMember 2020-01-01 2020-06-30 0001627281 ifrs-full:OrdinarySharesMember 2020-01-01 2020-06-30 0001627281 clls:ResearchAndDevelopmentExpensesMember 2020-01-01 2020-06-30 0001627281 clls:SellingGeneralAndAdministrativeExpenses1Member 2020-01-01 2020-06-30 0001627281 clls:PersonnelExpensesMember 2020-01-01 2020-06-30 0001627281 ifrs-full:SharePremiumMember 2020-01-01 2020-06-30 0001627281 ifrs-full:PlantsMember clls:ResearchAndDevelopmentMember 2020-01-01 2020-06-30 0001627281 clls:TherapeuticsMember clls:ResearchAndDevelopmentMember 2020-01-01 2020-06-30 0001627281 clls:ResearchAndDevelopmentMember 2020-01-01 2020-06-30 0001627281 clls:SellingGeneralAndAdministrationMember ifrs-full:PlantsMember 2020-01-01 2020-06-30 0001627281 clls:SellingGeneralAndAdministrationMember clls:TherapeuticsMember 2020-01-01 2020-06-30 0001627281 clls:SellingGeneralAndAdministrationMember 2020-01-01 2020-06-30 0001627281 ifrs-full:BuildingsMember ifrs-full:RightofuseAssetsMember 2020-01-01 2020-06-30 0001627281 ifrs-full:OfficeEquipmentMember ifrs-full:RightofuseAssetsMember 2020-01-01 2020-06-30 0001627281 ifrs-full:RightofuseAssetsMember 2020-01-01 2020-06-30 0001627281 clls:PerformanceStockUnitMember clls:CalyxtMember 2020-01-01 2020-06-30 0001627281 clls:RestrictedStockUnitMember 2020-01-01 2020-06-30 0001627281 ifrs-full:OperatingSegmentsMember ifrs-full:PlantsMember 2021-01-01 2021-06-30 0001627281 clls:TherapeuticsMember ifrs-full:OperatingSegmentsMember 2021-01-01 2021-06-30 0001627281 ifrs-full:OperatingSegmentsMember 2021-01-01 2021-06-30 0001627281 clls:EquityAwardsMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtMember clls:StockOption1Member 2021-01-01 2021-06-30 0001627281 clls:CommercialLitigationMember 2021-01-01 2021-06-30 0001627281 clls:PensionServiceCostMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtMember clls:StockOption1Member ifrs-full:BottomOfRangeMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtMember clls:StockOption1Member ifrs-full:TopOfRangeMember 2021-01-01 2021-06-30 0001627281 clls:SAFreeSharesMember 2021-01-01 2021-06-30 0001627281 ifrs-full:LandAndBuildingsMember 2021-01-01 2021-06-30 0001627281 clls:TechnicalEquipmentMember 2021-01-01 2021-06-30 0001627281 ifrs-full:FixturesAndFittingsMember 2021-01-01 2021-06-30 0001627281 ifrs-full:ConstructionInProgressMember 2021-01-01 2021-06-30 0001627281 ifrs-full:EliminationOfIntersegmentAmountsMember ifrs-full:PlantsMember 2021-01-01 2021-06-30 0001627281 ifrs-full:EliminationOfIntersegmentAmountsMember clls:TherapeuticsMember 2021-01-01 2021-06-30 0001627281 ifrs-full:EliminationOfIntersegmentAmountsMember 2021-01-01 2021-06-30 0001627281 clls:RestrictedStockUnitMember clls:CalyxtMember 2021-01-01 2021-06-30 0001627281 clls:SettlementOfEmployeeLitigationMember 2021-01-01 2021-06-30 0001627281 ifrs-full:EquityAttributableToOwnersOfParentMember 2021-01-01 2021-06-30 0001627281 ifrs-full:NoncontrollingInterestsMember 2021-01-01 2021-06-30 0001627281 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-06-30 0001627281 country:FR 2021-01-01 2021-06-30 0001627281 country:US 2021-01-01 2021-06-30 0001627281 clls:CellectisIncMember 2021-01-01 2021-06-30 0001627281 clls:CellectisBiologicsMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtIncMember 2021-01-01 2021-06-30 0001627281 clls:WarrantsMember 2021-01-01 2021-06-30 0001627281 clls:AssetsUnderConstructionMember clls:ParisMember 2021-01-01 2021-06-30 0001627281 clls:AssetsUnderConstructionMember stpr:NC 2021-01-01 2021-06-30 0001627281 ifrs-full:PlantsMember 2021-01-01 2021-06-30 0001627281 clls:TherapeuticsMember 2021-01-01 2021-06-30 0001627281 clls:StockOption1Member 2021-01-01 2021-06-30 0001627281 clls:EquityAwardsMember ifrs-full:BottomOfRangeMember 2021-01-01 2021-06-30 0001627281 clls:EquityAwardsMember ifrs-full:TopOfRangeMember 2021-01-01 2021-06-30 0001627281 ifrs-full:RetainedEarningsMember 2021-01-01 2021-06-30 0001627281 clls:CurrencyTranslationAdjustmentMember 2021-01-01 2021-06-30 0001627281 ifrs-full:OrdinarySharesMember 2021-01-01 2021-06-30 0001627281 ifrs-full:SharePremiumMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtMember clls:RestrictedPeriodMember 2021-01-01 2021-06-30 0001627281 clls:ResearchAndDevelopmentExpensesMember 2021-01-01 2021-06-30 0001627281 clls:SellingGeneralAndAdministrativeExpenses1Member 2021-01-01 2021-06-30 0001627281 clls:PersonnelExpensesMember 2021-01-01 2021-06-30 0001627281 clls:StockOption1Member 2021-01-01 2021-06-30 0001627281 clls:StockOption1Member clls:CalyxtMember 2021-01-01 2021-06-30 0001627281 clls:PensionMember 2021-01-01 2021-06-30 0001627281 ifrs-full:PlantsMember clls:ResearchAndDevelopmentMember 2021-01-01 2021-06-30 0001627281 clls:TherapeuticsMember clls:ResearchAndDevelopmentMember 2021-01-01 2021-06-30 0001627281 clls:ResearchAndDevelopmentMember 2021-01-01 2021-06-30 0001627281 clls:SellingGeneralAndAdministrationMember ifrs-full:PlantsMember 2021-01-01 2021-06-30 0001627281 clls:SellingGeneralAndAdministrationMember clls:TherapeuticsMember 2021-01-01 2021-06-30 0001627281 clls:SellingGeneralAndAdministrationMember 2021-01-01 2021-06-30 0001627281 clls:LossOnContractMember 2021-01-01 2021-06-30 0001627281 clls:EmployeeLitigationAndSeveranceMember 2021-01-01 2021-06-30 0001627281 ifrs-full:BuildingsMember ifrs-full:RightofuseAssetsMember 2021-01-01 2021-06-30 0001627281 ifrs-full:OfficeEquipmentMember ifrs-full:RightofuseAssetsMember 2021-01-01 2021-06-30 0001627281 ifrs-full:RightofuseAssetsMember 2021-01-01 2021-06-30 0001627281 clls:TechnicalEquipmentsMember 2021-01-01 2021-06-30 0001627281 clls:OtherEquipmentMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtIncAndCellectisSitesMember clls:OtherEquipmentMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtIncAndCellectisSitesMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtMember clls:PerformanceStockUnitMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtMember clls:PerformanceStockUnitMember 2021-01-01 2021-06-30 0001627281 clls:PerformanceStockUnitMember clls:CalyxtMember clls:PerformancePeriodMember 2021-01-01 2021-06-30 0001627281 clls:PerformanceStockUnitMember clls:CalyxtMember clls:RestrictedPeriodMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtMember clls:PerformanceStockUnitMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtMember clls:PerformanceStockUnitMember ifrs-full:BottomOfRangeMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtMember clls:PerformanceStockUnitMember ifrs-full:TopOfRangeMember 2021-01-01 2021-06-30 0001627281 clls:CalyxtIncMember clls:HighOleicSoyabeanMealMember 2021-01-01 2021-06-30 0001627281 clls:StateGuaranteedLoanMember clls:MajorBorrowingTransactionsMember 2021-01-01 2021-06-30 0001627281 clls:AtmFinancingProgramMember 2021-01-01 2021-06-30 0001627281 clls:RestrictedStockUnitMember 2021-01-01 2021-06-30 0001627281 clls:Allo715Member 2021-01-01 2021-06-30 0001627281 clls:RestrictedStockUnitMember clls:CalyxtMember 2021-01-01 2021-06-30 0001627281 ifrs-full:OperatingSegmentsMember ifrs-full:PlantsMember 2021-04-01 2021-06-30 0001627281 clls:TherapeuticsMember ifrs-full:OperatingSegmentsMember 2021-04-01 2021-06-30 0001627281 ifrs-full:OperatingSegmentsMember 2021-04-01 2021-06-30 0001627281 ifrs-full:EliminationOfIntersegmentAmountsMember ifrs-full:PlantsMember 2021-04-01 2021-06-30 0001627281 ifrs-full:EliminationOfIntersegmentAmountsMember clls:TherapeuticsMember 2021-04-01 2021-06-30 0001627281 ifrs-full:EliminationOfIntersegmentAmountsMember 2021-04-01 2021-06-30 0001627281 country:FR 2021-04-01 2021-06-30 0001627281 country:US 2021-04-01 2021-06-30 0001627281 ifrs-full:PlantsMember 2021-04-01 2021-06-30 0001627281 clls:TherapeuticsMember 2021-04-01 2021-06-30 0001627281 clls:PersonnelExpensesMember 2021-04-01 2021-06-30 0001627281 clls:SellingGeneralAndAdministrativeExpenses1Member 2021-04-01 2021-06-30 0001627281 clls:ResearchAndDevelopmentExpensesMember 2021-04-01 2021-06-30 0001627281 ifrs-full:PlantsMember clls:ResearchAndDevelopmentMember 2021-04-01 2021-06-30 0001627281 clls:TherapeuticsMember clls:ResearchAndDevelopmentMember 2021-04-01 2021-06-30 0001627281 clls:ResearchAndDevelopmentMember 2021-04-01 2021-06-30 0001627281 clls:SellingGeneralAndAdministrationMember ifrs-full:PlantsMember 2021-04-01 2021-06-30 0001627281 clls:SellingGeneralAndAdministrationMember clls:TherapeuticsMember 2021-04-01 2021-06-30 0001627281 clls:SellingGeneralAndAdministrationMember 2021-04-01 2021-06-30 0001627281 ifrs-full:PlantsMember ifrs-full:OperatingSegmentsMember 2020-04-01 2020-06-30 0001627281 ifrs-full:OperatingSegmentsMember clls:TherapeuticsMember 2020-04-01 2020-06-30 0001627281 ifrs-full:OperatingSegmentsMember 2020-04-01 2020-06-30 0001627281 ifrs-full:EliminationOfIntersegmentAmountsMember clls:TherapeuticsMember 2020-04-01 2020-06-30 0001627281 ifrs-full:EliminationOfIntersegmentAmountsMember 2020-04-01 2020-06-30 0001627281 country:FR 2020-04-01 2020-06-30 0001627281 country:US 2020-04-01 2020-06-30 0001627281 ifrs-full:PlantsMember 2020-04-01 2020-06-30 0001627281 clls:TherapeuticsMember 2020-04-01 2020-06-30 0001627281 clls:PersonnelExpensesMember 2020-04-01 2020-06-30 0001627281 clls:SellingGeneralAndAdministrativeExpenses1Member 2020-04-01 2020-06-30 0001627281 clls:ResearchAndDevelopmentExpensesMember 2020-04-01 2020-06-30 0001627281 ifrs-full:PlantsMember clls:ResearchAndDevelopmentMember 2020-04-01 2020-06-30 0001627281 clls:TherapeuticsMember clls:ResearchAndDevelopmentMember 2020-04-01 2020-06-30 0001627281 clls:ResearchAndDevelopmentMember 2020-04-01 2020-06-30 0001627281 clls:SellingGeneralAndAdministrationMember ifrs-full:PlantsMember 2020-04-01 2020-06-30 0001627281 clls:SellingGeneralAndAdministrationMember clls:TherapeuticsMember 2020-04-01 2020-06-30 0001627281 clls:SellingGeneralAndAdministrationMember 2020-04-01 2020-06-30 0001627281 clls:CarryingAmountAndValueMember 2020-12-31 0001627281 clls:EstimatedFairValueMember 2020-12-31 0001627281 ifrs-full:TradingSecuritiesMember 2020-12-31 0001627281 clls:PaycheckProtectionProgramLoanMember 2020-12-31 0001627281 clls:CellectisMember 2020-12-31 0001627281 clls:SAFreeSharesMember 2020-01-01 2020-12-31 0001627281 clls:WarrantsMember 2020-01-01 2020-12-31 0001627281 clls:StockOption1Member clls:CalyxtMember 2020-01-01 2020-12-31 0001627281 clls:StockOption1Member 2020-01-01 2020-12-31 0001627281 clls:CalyxtIncMember 2020-01-01 2020-12-31 0001627281 ifrs-full:LandAndBuildingsMember 2020-06-30 0001627281 clls:TechnicalEquipmentMember 2020-06-30 0001627281 ifrs-full:FixturesAndFittingsMember 2020-06-30 0001627281 ifrs-full:ConstructionInProgressMember 2020-06-30 0001627281 ifrs-full:BuildingsMember ifrs-full:RightofuseAssetsMember 2020-06-30 0001627281 ifrs-full:OfficeEquipmentMember ifrs-full:RightofuseAssetsMember 2020-06-30 0001627281 ifrs-full:RightofuseAssetsMember 2020-06-30 0001627281 clls:WarrantsMember 2019-01-01 2019-12-31 0001627281 clls:StockOption1Member 2019-01-01 2019-12-31 0001627281 clls:StockOption1Member clls:CalyxtMember 2019-01-01 2019-12-31 0001627281 clls:PerformanceStockUnitMember clls:CalyxtMember 2019-06-28 2019-06-28 0001627281 clls:CytoviaTherapeuticsIncMember 2021-02-12 0001627281 clls:TwoThousandEighteenStockOptionPlanMember 2021-03-01 2021-03-31 0001627281 clls:TwoThousandEighteenStockOptionPlanMember 2020-10-01 2020-10-31 0001627281 ifrs-full:OrdinarySharesMember 2019-12-31 0001627281 ifrs-full:SharePremiumMember 2019-12-31 0001627281 clls:CurrencyTranslationAdjustmentMember 2019-12-31 0001627281 ifrs-full:RetainedEarningsMember 2019-12-31 0001627281 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001627281 ifrs-full:EquityAttributableToOwnersOfParentMember 2019-12-31 0001627281 ifrs-full:NoncontrollingInterestsMember 2019-12-31 0001627281 ifrs-full:LandAndBuildingsMember 2019-12-31 0001627281 clls:TechnicalEquipmentMember 2019-12-31 0001627281 ifrs-full:FixturesAndFittingsMember 2019-12-31 0001627281 ifrs-full:ConstructionInProgressMember 2019-12-31 0001627281 ifrs-full:OrdinarySharesMember 2020-06-30 0001627281 ifrs-full:SharePremiumMember 2020-06-30 0001627281 ifrs-full:BuildingsMember ifrs-full:RightofuseAssetsMember 2019-12-31 0001627281 ifrs-full:RightofuseAssetsMember ifrs-full:OfficeEquipmentMember 2019-12-31 0001627281 ifrs-full:RightofuseAssetsMember 2019-12-31 0001627281 ifrs-full:RetainedEarningsMember 2020-06-30 0001627281 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001627281 ifrs-full:EquityAttributableToOwnersOfParentMember 2020-06-30 0001627281 ifrs-full:NoncontrollingInterestsMember 2020-06-30 0001627281 clls:CurrencyTranslationAdjustmentMember 2020-06-30 0001627281 ifrs-full:OrdinarySharesMember 2020-12-31 0001627281 ifrs-full:SharePremiumMember 2020-12-31 0001627281 clls:CurrencyTranslationAdjustmentMember 2020-12-31 0001627281 ifrs-full:RetainedEarningsMember 2020-12-31 0001627281 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001627281 ifrs-full:EquityAttributableToOwnersOfParentMember 2020-12-31 0001627281 ifrs-full:NoncontrollingInterestsMember 2020-12-31 0001627281 ifrs-full:LandAndBuildingsMember 2020-12-31 0001627281 clls:TechnicalEquipmentMember 2020-12-31 0001627281 ifrs-full:FixturesAndFittingsMember 2020-12-31 0001627281 ifrs-full:ConstructionInProgressMember 2020-12-31 0001627281 clls:RestrictedStockUnitMember clls:CalyxtMember 2020-12-31 0001627281 ifrs-full:PreviouslyStatedMember 2020-12-31 0001627281 clls:SAFreeSharesMember 2021-06-30 0001627281 clls:RestrictedStockUnitMember clls:CalyxtMember 2021-06-30 0001627281 clls:WarrantsMember 2021-06-30 0001627281 clls:StockOption1Member 2021-06-30 0001627281 clls:StockOption1Member clls:CalyxtMember 2021-06-30 0001627281 ifrs-full:PreviouslyStatedMember clls:PensionMember 2020-12-31 0001627281 ifrs-full:OrdinarySharesMember 2021-06-30 0001627281 ifrs-full:SharePremiumMember 2021-06-30 0001627281 clls:PensionMember 2021-06-30 0001627281 clls:LossOnContractMember 2021-06-30 0001627281 ifrs-full:PreviouslyStatedMember clls:EmployeeLitigationAndSeveranceMember 2020-12-31 0001627281 clls:EmployeeLitigationAndSeveranceMember 2021-06-30 0001627281 ifrs-full:PreviouslyStatedMember clls:CommercialLitigationMember 2020-12-31 0001627281 ifrs-full:BuildingsMember ifrs-full:RightofuseAssetsMember 2020-12-31 0001627281 ifrs-full:RightofuseAssetsMember ifrs-full:OfficeEquipmentMember 2020-12-31 0001627281 ifrs-full:RightofuseAssetsMember 2020-12-31 0001627281 clls:CommercialLitigationMember 2021-06-30 0001627281 clls:CalyxtMember clls:PerformanceStockUnitMember 2020-12-31 0001627281 clls:CalyxtMember clls:PerformanceStockUnitMember 2021-06-30 0001627281 ifrs-full:RetainedEarningsMember 2021-06-30 0001627281 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001627281 ifrs-full:EquityAttributableToOwnersOfParentMember 2021-06-30 0001627281 ifrs-full:NoncontrollingInterestsMember 2021-06-30 0001627281 clls:CurrencyTranslationAdjustmentMember 2021-06-30 0001627281 clls:SAFreeSharesMember 2019-12-31 0001627281 clls:WarrantsMember 2019-12-31 0001627281 clls:StockOption1Member 2019-12-31 0001627281 clls:StockOption1Member clls:CalyxtMember 2019-12-31 0001627281 clls:SAFreeSharesMember 2020-12-31 0001627281 clls:WarrantsMember 2020-12-31 0001627281 clls:StockOption1Member 2020-12-31 0001627281 clls:StockOption1Member clls:CalyxtMember 2020-12-31 iso4217:USD xbrli:shares xbrli:pure utr:Year iso4217:EUR iso4217:EUR xbrli:shares iso4217:USD xbrli:shares clls:Agreement utr:Y
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
6-K/A
(Amendment No. 1 to Report on Form
6-K
(Film No. 211148935)
 
 
Report of Foreign Private Issuer
Pursuant to Rule
13a-16
or
15d-16
under the Securities Exchange Act of 1934
Date of Report:
August 31, 2021
Commission File Number:
001-36891
 
 
Cellectis S.A.
(Exact Name of registrant as specified in its charter)
 
 
8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F:
Form 20-F   ☒            Form
40-F  ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1):  ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7):  ☐
 
 
 

Explanatory Note
This report on Form 6-K/A (this “Amendment”) filed by Cellectis S.A. (the “Company”) amends the Company’s report on Form 6-K, which included the Company’s unaudited condensed Consolidated Financial Statements for the three and six-month periods ended June 30, 2021 (the “Report”), filed with the U.S. Securities and Exchange Commission on August 5, 2021, solely to provide the financial statements formatted in iXBRL (Inline eXtensible Business Reporting Language) in accordance with Rule 405 of Regulation S-T and paragraph C.(6)(a)(ii) of the General Instructions to Form 6-K. Exhibit 101 includes information in Inline eXtensible Business Reporting Language.
Other than as expressly set forth above, this Amendment does not, and does not purport to, amend, revise, update or restate the information presented in the Report or reflect any events that have occurred after the Report was originally filed.
Exhibits
The following document, which is attached as an exhibit hereto, is incorporated by reference herein.
This report on Form
6-K
shall be deemed to be incorporated by reference in the registration statements of the Company on Form
F-3
(No.
333-238881)
and Form
S-8
(Nos.
333-204205,
333-214884,
333-222482,
333-227717
and 333-258514), to the extent not superseded by documents or reports subsequently filed.
 
Exhibit
  
Title
   
99.1    Cellectis S.A.’s interim report for the three- and
six-month
periods ended June 30, 2021.
   
101    The following materials from Cellectis S.A.’s Report on Form
6-K
formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Interim Statements of Consolidated Financial Position, (ii) the Unaudited Statements of Consolidated Operations, (iii) the Interim Statements of Consolidated Comprehensive Income (Loss), (iv) the Interim Statements of Consolidated Cash Flows, (v) the Statements of Changes in Consolidated Shareholders’ Equity, and (vi) Notes to the Interim Consolidated Financial Statements.

EXHIBIT INDEX
 
Exhibit
  
Title
   
99.1    Cellectis S.A.’s interim report for the three- and six-month period ended June 30, 2021.
   
101    The following materials from Cellectis S.A.’s Report on Form
6-K
formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Interim Statements of Consolidated Financial Position, (ii) the Unaudited Statements of Consolidated Operations, (iii) the Interim Statements of Consolidated Comprehensive Income (Loss), (iv) the Interim Statements of Consolidated Cash Flows, (v) the Statements of Changes in Consolidated Shareholders’ Equity, and (vi) Notes to the Interim Consolidated Financial Statements.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
 
CELLECTIS S.A.
(Registrant)
       
August
31
, 2021
 
 
 
By:
 
/s/ André Choulika
 
 
 
 
 
 
André Choulika
 
 
 
 
 
 
Chief Executive Officer